دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities
Alex K. Bryant, MD, MAS; Kyung Min Lee, PhD; Patrick R. Alba, MS; et al.
Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer
Diana R. Withrow, PhD; Harald Anderson, PhD; Gregory T. Armstrong, MD; et al.
Association of Changes in Cancer Therapy Over 3 Decades With Risk of Subsequent Breast Cancer Among Female Childhood Cancer SurvivorsA Report From the Childhood Cancer Survivor Study (CCSS)
Tara O. Henderson, MD, MPH; Qi Liu, MS; Lucie M. Turcotte, MD, MPH; et al.
Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaA Randomized Clinical Trial
Jingjing Miao, MD; Lin Wang, MD; Sze Huey Tan, PhD; et al.
Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer
Angela K. Green, MD, MSc; Sara M. Tabatabai, BS; Carol Aghajanian, MD; et al.
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Olivier J. van Not, MD; Rik J. Verheijden, BSc; Alfonsus J. M. van den Eertwegh, MD, PhD; et al.
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast CancerThe Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial
Pierre Loap, MD; Delphine Loirat, MD, PhD; Frederique Berger, PhD; et al.
Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain MetastasisA Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial
Joshua D. Palmer, MD; Brett G. Klamer, MS; Karla V. Ballman, PhD; et al.
Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status
Jithma P. Abeykoon, MD; Karen L. Rech, MD; Jason R. Young, MD; et al.
Comparing Trial and Real-world Adjuvant Oxaliplatin Delivery in Patients With Stage III Colon Cancer Using a Longitudinal Cumulative Dose
Michael Webster-Clark, PharmD, PhD; Alexander P. Keil, PhD; Nicholas Robert, MD; et al.
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
Chan Kim, MD, PhD; Hannah Yang, PhD; Ilhwan Kim, MD; et al.
Abdominal Extrarenal Involvement in Erdheim-Chester Disease in a Cohort of 304 Patients
Benjamin Dray, MD; Jean-François Emile, MD, PhD; Fleur  Cohen-Aubart, MD, PhD; et al.
Association Between Polycystic Ovary Syndrome and Risk of Pancreatic Cancer
Noah C. Peeri, PhD; Marco V. Landicino; C. Amethyst Saldia, BS; et al.
Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era
Maureen E. Canavan, PhD, MPH; Xiaoliang Wang, PhD, MPH; Mustafa S. Ascha, PhD; et al.
Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic
Meera V. Ragavan, MD, MPH; Nichole Legaspi, BS; Alyssa LaLanne, BA; et al.
Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With CancerA Narrative Review
Matthew G. Krebs, MD, PhD; Umberto Malapelle, PhD; Fabrice André, MD, PhD; et al.
Generalized Cutaneous Nodules on the Trunk and Extremities
Yu Xiao, MD; Shaomin Zhong, MD; Yang Wang, MD
All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring—Why Take the Slow Lane
Jan H. Beumer, PharmD, PhD, DABT; Edward Chu, MD; Salvatore J. Salamone, PhD
A Cast of Shadow on Postoperative Radiotherapy for pIIIA-N2 Non–Small Cell Lung Cancer?
Stefania Canova, MD; Stefano Arcangeli, MD; Diego Luigi Cortinovis, MD
Reexamining Social Determinants of Health Data Collection in the COVID-19 Era
Samyukta Mullangi, MD, MBA; Emeline M. Aviki, MD, MBA; Dawn L. Hershman, MD, MS
Treatment-Associated Breast Cancer Following Childhood CancerWhere Do We Go From Here?
Kelsey L. Corrigan, MD, MPH; Michael Roth, MD
Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial EnrollmentTime to Stop Tinkering Around the Edges
Jacquelyne J. Gaddy, MD, MSc; Cary P. Gross, MD
PSMA PET Scan
Daniel H. Kwon, MD; Ana I. Velazquez, MD, MSc; Ivan de Kouchkovsky, MD
Avoiding Checkmate—Playing Chess With Cancer
Aakash Desai, MD, MPH
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?
Michele Reni, MD; Marina Macchini, MD; Giulia Orsi, MD
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply
J. Annelie Suurmeijer, MD; Marc G. Besselink, MD, PhD; Hanneke W. M. van Laarhoven, MD, PhD
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality
Hein V. Stroomberg, PhD, MSc; Klaus Brasso, PhD, MD; Andreas Røder, PhD, MD
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply
Lars Björnebo, MD, MSc; Martin Eklund, PhD; Anna Lantz, MD, PhD
Methodologic Concerns in Secondary Analysis of KEYNOTE-048
Barbara Burtness, MD; Jianxin Lin, MS; Denis Souliéres, MD, MSc
Methodologic Concerns in Secondary Analysis of KEYNOTE-048—Reply
Yao Yu, MD; Eric J. Sherman, MD; Nancy Y. Lee, MD
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis
James H. B. Im, MPH; Ronald Chow, MS; Elizabeth Horn Prsic, MD
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis—Reply
Manali I. Patel, MD, MPH, MS; Kristopher Kapphahn, MS
